VM1, a triazole nucleoside analogue, downregulates the expression of HSF1, HSPs (HSP27, HSP70 and HSP90α) and androgen receptor (AR), offering potential benefits for prostate cancer therapy (Table 1) 186. This evidence concerns the gene AR and prostate cancer.